Generali Investments Towarzystwo Funduszy Inwestycyjnych Raises Stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Generali Investments Towarzystwo Funduszy Inwestycyjnych lifted its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 77.1% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 62,000 shares of the company’s stock after buying an additional 27,000 shares during the quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych’s holdings in Intellia Therapeutics were worth $723,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. Whipplewood Advisors LLC acquired a new stake in shares of Intellia Therapeutics in the fourth quarter worth approximately $40,000. KBC Group NV boosted its position in shares of Intellia Therapeutics by 62.4% in the fourth quarter. KBC Group NV now owns 6,093 shares of the company’s stock worth $71,000 after acquiring an additional 2,340 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Intellia Therapeutics by 27.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,674 shares of the company’s stock worth $77,000 after acquiring an additional 794 shares during the last quarter. AdvisorNet Financial Inc boosted its position in shares of Intellia Therapeutics by 96.4% in the fourth quarter. AdvisorNet Financial Inc now owns 10,085 shares of the company’s stock worth $118,000 after acquiring an additional 4,950 shares during the last quarter. Finally, LMG Wealth Partners LLC acquired a new stake in shares of Intellia Therapeutics in the fourth quarter worth approximately $130,000. 88.77% of the stock is currently owned by hedge funds and other institutional investors.

Intellia Therapeutics Stock Up 0.6 %

NTLA opened at $10.86 on Friday. The firm has a market capitalization of $1.11 billion, a P/E ratio of -2.00 and a beta of 1.80. The firm’s 50 day moving average is $10.92 and its 200-day moving average is $15.75. Intellia Therapeutics, Inc. has a 52-week low of $8.96 and a 52-week high of $34.87.

Insider Buying and Selling

In related news, CEO John M. Leonard sold 26,807 shares of Intellia Therapeutics stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $12.18, for a total value of $326,509.26. Following the completion of the sale, the chief executive officer now owns 941,115 shares in the company, valued at approximately $11,462,780.70. The trade was a 2.77 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Over the last quarter, insiders sold 29,000 shares of company stock worth $352,551. Insiders own 3.20% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently issued reports on NTLA. Wedbush reissued a “neutral” rating and issued a $10.00 target price (down from $14.00) on shares of Intellia Therapeutics in a research report on Friday, January 10th. Barclays decreased their target price on shares of Intellia Therapeutics from $76.00 to $55.00 and set an “overweight” rating on the stock in a research report on Friday, November 8th. Oppenheimer decreased their target price on shares of Intellia Therapeutics from $60.00 to $40.00 and set an “outperform” rating on the stock in a research report on Monday, January 13th. The Goldman Sachs Group reduced their price target on shares of Intellia Therapeutics from $19.00 to $12.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 14th. Finally, Wells Fargo & Company reduced their price target on shares of Intellia Therapeutics from $70.00 to $60.00 and set an “overweight” rating on the stock in a research report on Friday, January 10th. One analyst has rated the stock with a sell rating, six have given a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Intellia Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $48.71.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.